| Product Name | Pazopanib |
| Description |
Tyrosine kinase inhibitor |
| Purity | >98% |
| CAS No. | 444731-52-6 |
| Molecular Formula | C21H23N7O2S |
| Molecular Weight | 437.5 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Source | Synthetic |
| Appearance | White solid powder |
| SMILES | CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N |
| InChI | InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25) |
| InChIKey | CUIHSIWYWATEQL-UHFFFAOYSA-N |
| Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
| Cite This Product | Pazopanib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-506) |
| Alternative Names | 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide |
| Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
| PubChem ID | 10113978 |
| Scientific Background | Pazopanib is a multi-targeted tyrosine kinase inhibitor primarily used in oncology to inhibit angiogenesis via the HGF/c-MET and VEGF pathways. While its direct application in neuroscience is limited, its anti-angiogenic and anti-inflammatory properties may offer therapeutic potential in neuro-oncology and neuroinflammatory conditions. Ongoing research is exploring its role in modulating the tumor microenvironment in brain cancers such as glioblastoma. |
| References |
1. Outani H., et al. (2014) BMC Cancer. 14: 455. 2. Pick A.M., & Nystrom K.K. (2012) Clin. Ther. 34(3): 511–520. |
Reviews
There are no reviews yet.